Always inform your provider about any over-the-counter medications you're taking
The Regulatory Reality of 2026: What Actually Changed In late 2023, the FDA moved 19 peptides, including BPC-157, to what's known as "Category 2" status under its framework for bulk drug substances used in compounding, identifying them as substances that "may present significant safety risks." The concern, as stated in FDA guidance, centered on the limited large-scale human data and questions about immunogenicity
Your body often adjusts to these medications over time, and many side effects become less bothersome after a few weeks
doi: 10.1111/j.1439-0272.2007.00794.x 208 MoazzamASharmaRAgarwalA
Clinicians apply different decision-making logics depending on indication
30), draws its name from what she sees in her patientsnot just physical transformation, but emotional release